



Malmö 26 May 2023

PRESS RELEASE

Aptahem attends the BioStock Life Science Summit on 31 May 2023

Aptahem's CEO Mikael Lindstam is presenting the company and gives an update on the ongoing activities. The presentation, which is held in English, can be followed online on 31 May at 12.50 CET.

More information about the event is available on the BioStock Life Science Summit website:

<https://www.biostock.se/en/biostock-life-science-summit-may-2023/>

For further information:

Aptahem AB

Mikael Lindstam, CEO

Tel: +46 (0)766-33 36 99

E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.